Adrenal atrophy primary prevention

	Adrenal atrophy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Adrenal atrophy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Adrenal atrophy primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Adrenal atrophy primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Adrenal atrophy primary prevention
CDC on Adrenal atrophy primary prevention
Adrenal atrophy primary prevention in the news
Blogs on Adrenal atrophy primary prevention
Directions to Hospitals Treating Adrenal atrophy
Risk calculators and risk factors for Adrenal atrophy primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]

Overview

Primary prevention of the adrenal atrophy consists of avoiding overuse of exogenous corticosteroid drugs.

Primary prevention of the adrenal atrophy consists of avoiding overuse of exogenous corticosteroid drugs.^[1]

↑ Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ (February 2016). "Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 101 (2): 364–89. doi:10.1210/jc.2015-1710. PMC 4880116. PMID 26760044.